Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed.

ABSTRACT: Hepatic encephalopathy (HE) is a potentially reversible neurocognitive syndrome that occurs in patients with acute or chronic liver disease. Currently, most of the therapies for HE aim to reduce ammonia production or increase its elimination. To date, only two agents have been approved as treatments for HE: lactulose and rifaximin. Many other drugs have also been used, but data to support their use are limited, preliminary or lacking. The aim of this review is to provide an overview and discussion of the current development of treatments for HE. Data from ongoing clinical trials in HE were obtained from the ClinicalTrials.gov website, and a breakdown analysis of studies that were active on August 19th, 2022, was performed. Seventeen registered and ongoing clinical trials for therapeutics t

SUBMITTER: Balzano T 

PROVIDER: S-EPMC10047473 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature